The Pharma Data

APRIL 22, 2023

While no cure is available for MS, existing disease-modifying therapies in the form of small molecule and protein drugs either directly target the self-reactive immune cells or broadly dampen inflammation. “Current MS therapies do not specifically target myeloid cells.

Therapies 40

Therapies Immune Response Small Molecule Engineering 40

Drug Target Review

NOVEMBER 6, 2023

2 It is this complexity that necessitates powerful, targeted combination therapies. 4, 5 More recently, new combination regimens have emerged that incorporate targeted therapies to treat a variety of blood cancers, including multiple myeloma (MM), chronic lymphocytic leukaemia (CLL) and acute myelogenous leukaemia (AML).

Small Molecule 111

Small Molecule Therapies Treatment Immune Response 111

Drug Discovery World

FEBRUARY 27, 2023

For RNA, we’ve seen its success with Covid-19 vaccines and the approval of the first-ever RNA-targeting small molecule, risdiplam, for treating spinal muscular atrophy (SMA). Do you have any therapeutic targets in mind for your first small molecule drug candidate? RT : Currently, we are developing our internal pipeline.

RNA 130

RNA Science Small Molecule Engineering 130

Drug Discovery World

APRIL 8, 2024

The company has participated in, and made possible, numerous AACR scientific meetings and think tanks where leaders from the national and international cancer research community have disseminated their novel findings. “On

DNA 130

DNA Small Molecule Science Treatment 130

LifeSciVC

JANUARY 16, 2024

These are incredible forecasts and CAGRs, which if we assume directionally correct, rely not only on steady growth for approved therapies but also a substantial success rate of, and continued investment in, the development pipeline. Small molecule GLP1s?

Small Molecule 139

Small Molecule Trials Therapies Disease 139

Drug Discovery World

OCTOBER 16, 2023

A company within this ecosystem is STORM Therapeutics, a clinical stage biotechnology company creating novel small molecule therapies that inhibit RNA modifying enzymes (RME) for use in oncology and other diseases. CellProthera also appointed the Newcastle Centre for Life’s GMP cell therapy centre to produce the ATMP.”

Drugs 189

Drugs Science Therapies Targeted Protein Degradation 189

Drug Discovery World

APRIL 27, 2023

Pegcetacoplan, an injectable treatment, is the first medication to use targeted C3 therapy to diffuse the harmful three- pronged “complement cascade” triggered by GA, a physiological response that attacks and destroys healthy tissue. We’re observing many stakeholders move to San Diego from other US hubs like Boston.

Small Molecule 130

Small Molecule Science Drugs FDA Approval 130

The Pharma Data

MAY 15, 2023

Through the acquisition, Gilead gains rights to a portfolio of small molecule inhibitors targeting PARP1 for oncology and MK2 for inflammatory diseases that could enter clinical trials later this year. XinThera is backed by a group of international investors including Foresite Capital, OrbiMed Advisors, LLC and TTM Capital.

Small Molecule 40

Small Molecule DNA Immune Response Science 40

LifeSciVC

APRIL 2, 2024

And the experience of those around you, including Board members and internal investors. We are confident that there is room for improvement over existing cystic fibrosis (CF) therapies because we have not yet achieved fully normalized function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein.

Science 67

Science Small Molecule International Clinical Development 67

PLOS: DNA Science

SEPTEMBER 5, 2024

Gleevec is a small molecule that interferes with entry of an enzyme – a tyrosine kinase – that enables growth signals to enter specific cells and trigger division. A name ending in “nib” means a small molecule that inhibits an enzyme called a kinase, and is short for “inhibit.”

Treatment 52

Treatment FDA Approval DNA Small Molecule 52

Drug Discovery World

JUNE 5, 2023

How best to communicate this strategy to both internal and external stakeholders? New approaches to partnering In this event in the Biotech track, Clive Cookson, Science Editor at the Financial Times, interviewed John McDonald, Corporate Vice President, Global R&D Business Development, Novo Nordisk. How to improve its pipeline?

Small Molecule 130

Small Molecule Treatment Science Disease 130

Drug Discovery World

JULY 17, 2024

Imperial College spinout NK:IO was awarded a £1.6m ($2m) Innovate UK New Cancer Therapeutics grant in 2023 to develop a pioneering NK cell therapy. DS: How can NK cell therapy tackle the limitations of cancer immunotherapy? Diana Spencer catches up with Co-Founder Mike Romanos to find out more. Six have been approved since 2017.

Therapies 130

Therapies Engineering Small Molecule Clinical Development 130

Drug Discovery World

APRIL 25, 2023

Amplify Therapeutics boasts disease-modifying therapies for Gaucher disease and genetic subgroups of Parkinson’s disease. In total, BII’s start-ups have raised over €333 million in external funding from both local and international investors.

Science 130

Science Small Molecule Disease Government 130

The Pharma Data

OCTOBER 6, 2021

The companies do not expect the introduction of booster doses in the United States and the EU, if authorized, to impact the existing supply agreements in place with governments and international health organizations around the world. About Pfizer: Breakthroughs That Change Patients’ Lives.

Vaccine 52

Vaccine Small Molecule Government Therapies 52

Drug Target Review

NOVEMBER 22, 2023

Whilst TGF-β is an attractive target for cancer therapy because of its critical role in promoting tumor aggressiveness, immune escape and resistance to therapy, activation of alternative resistance pathways has hindered drug development attempts in the past.

Licensing 52

Licensing Licensing Small Molecule Therapies 52

The Pharma Data

OCTOBER 15, 2020

a leading biotechnology company developing small molecule therapeutics based on its proprietary uSMITE platform of targeted protein degradation technology, today announced that the company’s internal program to develop selective degraders that target key proteins within the TRK family has been published by the Journal of Medicinal Chemistry.

Targeted Protein Degradation 52

Targeted Protein Degradation Small Molecule Science Disease 52

Agency IQ

NOVEMBER 3, 2023

regulatory landscape for probiotics and other microbiome-based therapies Probiotics, a type of microbiome-based therapy containing live micro-organisms, are broadly available on drug store and grocery store shelves, but the regulatory classifications for products containing the same micro-organism can differ dramatically.

Therapies 40

Therapies Science FDA Production 40

The Pharma Data

APRIL 28, 2021

OSAKA, Japan, April 28, 2021 – Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (“Takeda”) today announced that it was awarded by the International Society for Pharmaceutical Engineering (ISPE) for the 2021 Facility Of the Year Awards (FOYA) in two categories.

Packaging 52

Packaging Small Molecule Pharmaceutical Companies Engineering 52

The Pharma Data

MAY 16, 2022

About Digestive Disease Week® Digestive Disease Week (DDW) is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery.

Disease 40

Disease Small Molecule Treatment Trials 40

The Pharma Data

JANUARY 17, 2021

The study enrolled 5,050 patients who received either vericiguat or placebo in combination with available heart failure therapies. Myelosuppression happens when radiation damages internal organs, including bone marrow. HFrEF was formerly known as systolic heart failure. The NDA was built on data from the Phase III VICTORIA trial.

FDA 52

FDA Small Molecule Immune Response Hospitals 52

The Pharma Data

OCTOBER 18, 2020

Dr. Berk most recently has served as a consultant to several companies developing oncology therapies. Dr. Berk completed his internship, residency, and fellowship in internal medicine, hematology, and medical oncology at the Weill Cornell Medical College and New York Presbyterian Hospital, where he also served as a faculty member.

Small Molecule 40

Small Molecule Clinical Development Clinical Trials Licensing 40

The Pharma Data

JANUARY 19, 2021

TCR 2 is developing novel T-cell therapies for solid tumors and hematological cancers. The company is using its pioneering FasTCAR and TruUCAR technology platforms to discover and develop breakthrough cell therapies. Its lead candidate is CLN-081, an oral small molecule designed to be a next-generation, irreversible EGFR inhibitor.

Small Molecule 52

Small Molecule Laboratories Trials Immune Response 52

The Pharma Data

MARCH 1, 2022

“There is a major unmet need for new therapies that can help improve cognitive function in patients suffering from difficult-to-treat neurologic diseases,” said Tom Hudson, M.D., senior vice president, R&D, chief scientific officer, AbbVie. “I am delighted with the closing of this deal.

Small Molecule 52

Small Molecule Licensing Licensing Disease 52

The Pharma Data

NOVEMBER 29, 2020

1 Meanwhile, these MDM2 inhibitors present some challenges, including dose-limiting hematological toxicities, thus the urgent need to develop new generation of MDM2-targeting therapies in the treatment of cancer. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 inhibitors) in clinical trials for cancer treatment.

Licensing 40

Licensing Licensing Small Molecule Clinical Trials 40

The Pharma Data

NOVEMBER 23, 2020

His most recent position was at Amgen as Director Global Business Development – Transactions, a position he assumed in August 2019 following the acquisition of Nuevolution, a Danish small molecule development company, at which he led the commercial and business activities as Chief Business Officer.

Clinical Trials 52

Clinical Trials Small Molecule Pharmaceutical Companies Licensing 52

The Pharma Data

NOVEMBER 18, 2020

Title: A phase I cohort expansion trial of OBI-833 in non-small cell lung cancer patients. Department of Internal Medicine, Tri-Service General Hospital, Taipei, Taiwan. .” Presentation number: 397P / Poster: ID 680. Presenter: Ching-Liang Ho MD, et.al. Session Title: E-poster Display session – Thoracic tumours, metastatic.

Vaccine 52

Vaccine Small Molecule Immune Response Hospitals 52

The Pharma Data

DECEMBER 17, 2020

Most recently, Cadavid served as senior vice president and Head of Clinical Development at Fulcrum Therapeutics where he led the development of multiple small molecules for the treatment of genetically defined rare diseases. Goater is CEO at Surface Oncology, an immuno-oncology company developing next-generation antibody therapies.

Small Molecule 52

Small Molecule Engineering Pharmaceuticals Clinical Development 52

The Pharma Data

JANUARY 13, 2021

The patent application is titled “Anti-CD154 Antibodies and Uses Thereof” and published under International Publication No. International Immunol. (11):1583 The CNS portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. WO 2021/001458 A1. Structure.

Pharmaceuticals 52

Pharmaceuticals Small Molecule Vaccine Protein Expression 52

KIF1A

JUNE 30, 2023

This program helped obtain wheelchairs for 2 KAND patients and a vibration therapy plate to help one patient with their circulation. With these models established, we are preparing to test our first batch of small molecules drugs later this year! It also happens to be International Superhero Day.

Small Molecule 52

Small Molecule Treatment Doctors Research 52

The Pharma Data

JANUARY 7, 2021

As CEO of Freeline, a liver-directed gene therapy company, she scaled the company from preclinical stage to a fully integrated biotechnology organization, which included a broad, internally developed pipeline, two programs in clinical development and a commercial-scale, high-quality CMC and manufacturing platform.

Small Molecule 52

Small Molecule Clinical Development Production Science 52

The Pharma Data

FEBRUARY 18, 2022

Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals.

Vaccine 40

Vaccine Production Small Molecule Compliance 40

NIH Director's Blog: Drug Development

MAY 21, 2020

Just one infusion of this combination antibody therapy lowered the amount of viral genetic material in the animals’ lungs by as much as 30 percent compared to the amount in untreated animals. Meanwhile, there’s been other impressive recent progress towards the development of monoclonal antibody therapies for COVID-19.

Virus 52

Virus Vaccine Laboratories Small Molecule 52

The Pharma Data

DECEMBER 13, 2020

RLY-1971 has the potential to serve as a backbone for combination therapy across numerous solid tumors and therefore represents an encouraging approach for cancer patients,” said Sanjiv Patel, M.D., To access the live call, please dial 1 (833) 540-1168 (domestic) or 1 (929) 517-0359 (international) and refer to conference ID 8792127.

Licensing 40

Licensing Licensing Clinical Trials Small Molecule 40

The Pharma Data

JULY 15, 2021

Vincent’s Institute of Medical Research (SVI)’s multi-year research collaboration with Janssen Pharmaceuticals, Inc. Vincent’s Institute of Medical Research (SVI)’s multi-year research collaboration with Janssen Pharmaceuticals, Inc.

Government 52

Government Science Pharmaceuticals Pharmaceutical Companies 52

The Pharma Data

JANUARY 3, 2021

Sixty-two percent of patients were treated with prior PD(L)-1 containing therapy, and the arms were well balanced. Alternatively, the call may be accessed by dialing (855) 783-2599 (domestic) or (631) 485-4787 (international) and referring to conference ID 5824089. SOUTH SAN FRANCISCO, Calif., Median PFS was 9.2 Exelixis, Inc.

Trials 52

Trials Clinical Trials Small Molecule Therapies 52

The Pharma Data

DECEMBER 14, 2020

The effectiveness of standard therapy with TMZ is limited because the response of GBM to TMZ is dependent upon the expression of the DNA repair enzymatic protein, O 6 -alkylguanine DNA alkyltransferase (MGMT). At the stage of GBM relapse and recurrence, no effective therapy strategies currently exist. Contact.

DNA 52

DNA Clinical Trials Drugs Therapies 52

The Pharma Data

NOVEMBER 22, 2020

We believe we are well prepared to press forward given our strong balance sheet and pioneering leadership in the development of muscle-directed therapies.”. We look forward to rapidly advancing next steps for omecamtiv mecarbil , which we expect will include discussions with regulatory authorities. Terms of Termination.

Clinical Trials 52

Clinical Trials Licensing Licensing Trials 52